Biotech Values

[poorgradstudent]

Not clear to me that the newer antibodies have a "fusion" like the lead drug. In any event, I realize this is very early stage work and plenty could go wrong but at just over $100M fully-diluted market cap and one of the only public ways possible to play what sounds like an emerging target in CD47, I'll continue to take my chances, for better or worse.

Sure.

But the lead drug is the fusion protein. Without a single human yet infused with the lead drug, I'm not sure people are already looking at the pipeline as a source of support.

Anyways, I think this is tangential to my concern. It may or may not be a valid one, but I'd like to know.